The Ozempic SmPC warns about the risk of dehydration and potential acute kidney injury with significant vomiting or diarrhoea
Triple-Hormone-Receptor Agonist Retatrutide for Obesity Phase 2, NEJM , 2023 ClinicalTrials.gov TRIUMPH-1 (NCT05929066), TRIUMPH-2 (NCT05929079), TRIUMPH-3 (NCT05882045), TRIUMPH-4 (NCT05931367) FDA Wegovy prescribing information, 2025 FDA Zepbound (tirzepatide) prescribing information, 2024 Medical disclaimer: This article is for informational purposes only
In control conditions, a strong, palatability-driven anticipatory effect was found in S1, followed by a complementary positive contrast effect in S2
H., Orchard, T
Package Contents : Toner equipped with a fine-mist dispensing mechanism
Always consult a qualified healthcare professional before starting, stopping, restarting, switching, or changing Zepbound, Mounjaro, tirzepatide, diabetes medication, or any other treatment.